|
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. |
|
|
Stock and Other Ownership Interests - Gilead Sciences (I) |
Patents, Royalties, Other Intellectual Property - 3 patents pertaining medtech, but none is licensed |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche/Genentech |
Consulting or Advisory Role - Guardant Health AMEA |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Abbvie/Genentech; Amgen; AstraZeneca; Bristol-Myers Squibb; Ipsen; Novartis |
Speakers' Bureau - Bayer; Eisai; Lilly; MSD Oncology; Sanofi/Aventis; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; DKSH; Lilly; MSD; Roche; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Merck; MSD; Novartis; Taiho Pharmaceutical |
Research Funding - MSD; Paxman |
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Roche; Taiho Pharmaceutical |